文献速递乳腺病理细胞病理与分子病理

骨转移乳腺癌激素受体与HER2评估:FNA细胞块与脱钙空芯针活检比较

Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
PubMed 文献 · Cancer Cytopathol · 2019-12-28

本研究比较了27例乳腺癌骨转移患者的FNA细胞块与同期脱钙空芯针活检在ER、PR、HER2免疫组化评估上的一致性。结果显示ER、PR、HER2一致率分别为89%、67%、93%,ER和PR分别约11%和33%的配对出现重大不一致,但两种方法总体均可用于临床决策。

要点

  • FNA细胞块与脱钙空芯针活检评估ER、PR、HER2的一致率分别为89%、67%、93%。
  • ER和PR的重大不一致(阳性 vs 阴性)分别约见于11%和33%的配对样本。
  • 两种方法均可接受用于乳腺癌骨转移的ER、PR、HER2临床评估。

核心结论

  • FNA细胞块和脱钙空芯针活检均是评估乳腺癌骨转移ER、PR、HER2的可接受方法,可用于临床决策。

研究设计与样本

  • 选取同时接受空芯针活检和FNA采样的乳腺癌骨转移患者,在FNA细胞块与同期脱钙空芯针活检中行ER、PR、HER2免疫组化,共27例患者配对样本。

主要发现

  • FNA细胞块与空芯针活检配对样本的ER、PR、HER2一致率分别为89%、67%、93%。
  • ER免疫组化重大不一致约见于11%的FNA/空芯针配对,PR重大不一致约见于33%的配对。
  • ER免疫组化不一致的配对中,FNA与空芯针的ESR1 mRNA水平相似,多数病例不能以此解释ER表达差异。
  • 27对中有2对HER2免疫组化结果不同,空芯针为阴性而FNA细胞块为不确定(2+),两例既往FISH均显示HER2扩增。

关键数值与推荐

  • ER、PR免疫组化核染色差异不超过30%定义为次要不一致,临床相关变化(阳性 vs 阴性)定义为重大不一致。

临床怎么用

  • 骨转移乳腺癌的ER、PR、HER2评估可选用FNA细胞块或脱钙空芯针活检,但需知晓PR不一致率较高。

局限性

  • 样本量仅27例配对,结论的普适性需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) guide the clinical management of breast cancer metastases. Decalcification of bone core needle biopsies (CNBs) can affect IHC. In the current study, the authors sought to define whether fine-needle aspiration (FNA) would be a better alternative to CNB for reliable IHC. METHODS: Patients with breast cancer metastases to bone that were sampled by both CNB and FNA were selected. ER, PR, and HER2 were performed in FNA cell blocks (FNA-CBs) and concurrent decalcified CNBs. Discrepancies were classified as minor when there was a difference of up to 30% nuclear staining in IHC for ER and PR between paired samples and as major when a clinically relevant change was observed (ie, positive vs negative). Quantitative reverse transcriptase-polymerase chain reaction of ESR1 messenger RNA levels was performed on FNA/CNB pairs with discrepancies for ER IHC. IHC status of the primary breast carcinoma was recorded. RESULTS: Concordance rates for ER, PR, and HER2 were 89%, 67%, and 93%, respectively, between FNA-CB and CNB pairs from 27 patients. Major discrepancies were noted in approximately 11% of FNA/CNB pairs for ER IHC and in 33% of FNA/CNB pairs for PR. ESR1 messenger RNA levels of FNA/CNB matched samples were similar and did not explain the differences in ER IHC expression in the majority of cases. Two of 27 FNA/CNB pairs had different results for HER2 IHC that changed from negative on CNB to equivocal (2+) on FNA-CB. Both cases had prior HER2 amplification by fluorescence in situ hybridization. CONCLUSIONS: FNA-CB and CNB appear to constitute acceptable methods for the assessment of ER, PR, and HER2 for clinical decision making.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Zeng J, Piscuoglio S, Aggarwal G, et al. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. Cancer Cytopathol. 2019. PMID: 31883437. doi:10.1002/cncy.22226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。